1. Surrogate endpoints in clinical trials: Definition and operational criteria;Prentice;Stat Med,1989
2. Surrogate endpoints in clinical trials: Cancer;Ellenberg;Stat Med,1989
3. Alonso A, Bigirumurame T, Burzykowski T, Buyse M, Molenberghs G, Muchene L, et al. Applied Surrogate Endpoint Evaluation Methods with SAS and R. 0 ed. Chapman and Hall/CRC; 2016. 10.1201/9781315372662.
4. National Archives and Records Administration. § 601.41 Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. Code Fed Regul n.d. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-F/part-601/subpart-E/section-601.41 (accessed September 7, 2022).
5. US Food and Drug Administration. Accelerated Approval n.d. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/accelerated-approval (accessed September 7, 2022).